{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:44:57Z","timestamp":1784133897198,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology (MOST), Taiwan","doi-asserted-by":"publisher","award":["107-2314-B-002-268-MY2"],"award-info":[{"award-number":["107-2314-B-002-268-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital, Taiwan","doi-asserted-by":"publisher","award":["106-3672"],"award-info":[{"award-number":["106-3672"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital, Taiwan","doi-asserted-by":"publisher","award":["107-4077"],"award-info":[{"award-number":["107-4077"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital, Taiwan","doi-asserted-by":"publisher","award":["108-4137"],"award-info":[{"award-number":["108-4137"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.canlet.2019.12.005","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T21:17:35Z","timestamp":1575580655000},"page":"27-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma"],"prefix":"10.1016","volume":"471","author":[{"given":"Po-Ming","family":"Chow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing-Hwa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Lin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chou","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-How","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2019.12.005_bib1","series-title":"F1000Res","first-page":"307","article-title":"Renal cell carcinoma: a review of biology and pathophysiology","volume":"vol. 7","author":"Nabi","year":"2018"},{"key":"10.1016\/j.canlet.2019.12.005_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Genome Atlas Research, Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.12.005_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1541-7786.MCR-12-0117","article-title":"State of the science: an update on renal cell carcinoma","volume":"10","author":"Jonasch","year":"2012","journal-title":"Mol. Cancer Res. : MCR"},{"key":"10.1016\/j.canlet.2019.12.005_bib4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.12.005_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2019.12.005_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.12.005_bib7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.12.005_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.12.005_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2019.12.005_bib10","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2019.12.005_bib11","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.canlet.2019.12.005_bib12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.12.005_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5500\/wjt.v2.i5.74","article-title":"Antineoplastic effects of mammalian target of rapamycine inhibitors","volume":"2","author":"Salvadori","year":"2012","journal-title":"World J. Transplant."},{"key":"10.1016\/j.canlet.2019.12.005_bib14","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1517\/14656566.2013.832202","article-title":"Targeting angiogenesis in renal cell carcinoma","volume":"14","author":"Posadas","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.canlet.2019.12.005_bib15","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nature13393","article-title":"Targeting transcription regulation in cancer with a covalent CDK7 inhibitor","volume":"511","author":"Kwiatkowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2019.12.005_bib16","series-title":"F1000Research","first-page":"5","article-title":"Strategically targeting MYC in cancer","author":"Posternak","year":"2016"},{"key":"10.1016\/j.canlet.2019.12.005_bib17","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ccell.2014.10.019","article-title":"Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor","volume":"26","author":"Christensen","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2019.12.005_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-dependent transcriptional addiction in triple-negative breast cancer","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2019.12.005_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.canlet.2019.12.005_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/btm2.10082","article-title":"Schedule dependent synergy of gemcitabine and doxorubicin: improvement of in vitro efficacy and lack of in vitro-in vivo correlation","volume":"3","author":"Vogus","year":"2018","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.canlet.2019.12.005_bib21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.4161\/auto.19653","article-title":"MTORC1 functions as a transcriptional regulator of autophagy by preventing nuclear transport of TFEB","volume":"8","author":"Martina","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2019.12.005_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1158\/2159-8290.CD-17-0461","article-title":"Suppression of adaptive responses to targeted cancer therapy by transcriptional repression","volume":"8","author":"Rusan","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2019.12.005_bib23","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.12.005_bib24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2019.12.005_bib25","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2019.12.005_bib26","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.celrep.2017.07.021","article-title":"Human TFIIH kinase CDK7 regulates transcription-associated chromatin modifications","volume":"20","author":"Ebmeier","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2019.12.005_bib27","article-title":"THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors","volume":"8","author":"Cayrol","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2019.12.005_bib28","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/0008-5472.CAN-16-2546","article-title":"Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2019.12.005_bib29","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1038\/oncsis.2017.33","article-title":"Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma","volume":"6","author":"Greenall","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2019.12.005_bib30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41401-018-0187-3","article-title":"THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism","volume":"40","author":"Cheng","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2019.12.005_bib31","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.7314\/APJCP.2012.13.6.2739","article-title":"beta-Elemene induces apoptosis in human renal-cell carcinoma 786-0 cells through inhibition of MAPK\/ERK and PI3K\/Akt\/mTOR signalling pathways","volume":"13","author":"Zhan","year":"2012","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.canlet.2019.12.005_bib32","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.canlet.2019.12.005_bib33","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1158\/1078-0432.CCR-10-2372","article-title":"Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma","volume":"17","author":"Ma","year":"2011","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Canc. Res."},{"key":"10.1016\/j.canlet.2019.12.005_bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2015.01.015","article-title":"MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies","volume":"363","author":"Kuo","year":"2015","journal-title":"Cancer Lett."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383519306111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:44:44Z","timestamp":1759592684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383519306111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":34,"alternative-id":["S0304383519306111"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2019.12.005","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2019.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}